139 related articles for article (PubMed ID: 24203458)
1. Estimation of tenofovir's population pharmacokinetic parameters without reliable dosing histories and application to tracing dosing history using simulation strategies.
Chaturvedula A; Fossler MJ; Hendrix CW
J Clin Pharmacol; 2014 Feb; 54(2):150-60. PubMed ID: 24203458
[TBL] [Abstract][Full Text] [Related]
2. MTN-001: randomized pharmacokinetic cross-over study comparing tenofovir vaginal gel and oral tablets in vaginal tissue and other compartments.
Hendrix CW; Chen BA; Guddera V; Hoesley C; Justman J; Nakabiito C; Salata R; Soto-Torres L; Patterson K; Minnis AM; Gandham S; Gomez K; Richardson BA; Bumpus NN
PLoS One; 2013; 8(1):e55013. PubMed ID: 23383037
[TBL] [Abstract][Full Text] [Related]
3. Tenofovir and tenofovir disoproxil fumarate pharmacokinetics from intravaginal rings.
Moss JA; Baum MM; Malone AM; Kennedy S; Kopin E; Nguyen C; Gilman J; Butkyavichene I; Willis RA; Vincent KL; Motamedi M; Smith TJ
AIDS; 2012 Mar; 26(6):707-10. PubMed ID: 22210639
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics and placental transfer of single-dose tenofovir 1% vaginal gel in term pregnancy.
Beigi R; Noguchi L; Parsons T; Macio I; Kunjara Na Ayudhya RP; Chen J; Hendrix CW; Mâsse B; Valentine M; Piper J; Watts DH
J Infect Dis; 2011 Nov; 204(10):1527-31. PubMed ID: 21930612
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics and safety of tenofovir in HIV-infected women during labor and their infants during the first week of life.
Mirochnick M; Taha T; Kreitchmann R; Nielsen-Saines K; Kumwenda N; Joao E; Pinto J; Santos B; Parsons T; Kearney B; Emel L; Herron C; Richardson P; Hudelson SE; Eshleman SH; George K; Fowler MG; Sato P; Mofenson L;
J Acquir Immune Defic Syndr; 2014 Jan; 65(1):33-41. PubMed ID: 23979002
[TBL] [Abstract][Full Text] [Related]
6. RMP-02/MTN-006: A phase 1 rectal safety, acceptability, pharmacokinetic, and pharmacodynamic study of tenofovir 1% gel compared with oral tenofovir disoproxil fumarate.
Anton PA; Cranston RD; Kashuba A; Hendrix CW; Bumpus NN; Richardson-Harman N; Elliott J; Janocko L; Khanukhova E; Dennis R; Cumberland WG; Ju C; Carballo-Diéguez A; Mauck C; McGowan I
AIDS Res Hum Retroviruses; 2012 Nov; 28(11):1412-21. PubMed ID: 22943559
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics of antiretroviral regimens containing tenofovir disoproxil fumarate and atazanavir-ritonavir in adolescents and young adults with human immunodeficiency virus infection.
Kiser JJ; Fletcher CV; Flynn PM; Cunningham CK; Wilson CM; Kapogiannis BG; Major-Wilson H; Viani RM; Liu NX; Muenz LR; Harris DR; Havens PL;
Antimicrob Agents Chemother; 2008 Feb; 52(2):631-7. PubMed ID: 18025112
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of an increased atazanavir dose with and without tenofovir during the third trimester of pregnancy.
Kreitchmann R; Best BM; Wang J; Stek A; Caparelli E; Watts DH; Smith E; Shapiro DE; Rossi S; Burchett SK; Hawkins E; Byroads M; Cressey TR; Mirochnick M
J Acquir Immune Defic Syndr; 2013 May; 63(1):59-66. PubMed ID: 23392467
[TBL] [Abstract][Full Text] [Related]
9. Adherence and acceptability in MTN 001: a randomized cross-over trial of daily oral and topical tenofovir for HIV prevention in women.
Minnis AM; Gandham S; Richardson BA; Guddera V; Chen BA; Salata R; Nakabiito C; Hoesley C; Justman J; Soto-Torres L; Patterson K; Gomez K; Hendrix CW
AIDS Behav; 2013 Feb; 17(2):737-47. PubMed ID: 23065145
[TBL] [Abstract][Full Text] [Related]
10. Single dose pharmacokinetics of oral tenofovir in plasma, peripheral blood mononuclear cells, colonic tissue, and vaginal tissue.
Louissaint NA; Cao YJ; Skipper PL; Liberman RG; Tannenbaum SR; Nimmagadda S; Anderson JR; Everts S; Bakshi R; Fuchs EJ; Hendrix CW
AIDS Res Hum Retroviruses; 2013 Nov; 29(11):1443-50. PubMed ID: 23600365
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetic modelling of efavirenz, atazanavir, lamivudine and tenofovir in the female genital tract of HIV-infected pre-menopausal women.
Dumond JB; Nicol MR; Kendrick RN; Garonzik SM; Patterson KB; Cohen MS; Forrest A; Kashuba AD
Clin Pharmacokinet; 2012 Dec; 51(12):809-22. PubMed ID: 23044523
[TBL] [Abstract][Full Text] [Related]
12. Population pharmacokinetics of tenofovir in HIV-1-infected pediatric patients.
Bouazza N; Urien S; Hirt D; Frange P; Rey E; Benaboud S; Foissac F; Blanche S; Tréluyer JM
J Acquir Immune Defic Syndr; 2011 Nov; 58(3):283-8. PubMed ID: 21857359
[TBL] [Abstract][Full Text] [Related]
13. Biphasic elimination of tenofovir diphosphate and nonlinear pharmacokinetics of zidovudine triphosphate in a microdosing study.
Chen J; Flexner C; Liberman RG; Skipper PL; Louissaint NA; Tannenbaum SR; Hendrix CW; Fuchs EJ
J Acquir Immune Defic Syndr; 2012 Dec; 61(5):593-9. PubMed ID: 23187888
[TBL] [Abstract][Full Text] [Related]
14. Age-related differences in plasma and intracellular tenofovir concentrations in HIV-1-infected children, adolescents and adults.
Baheti G; King JR; Acosta EP; Fletcher CV
AIDS; 2013 Jan; 27(2):221-5. PubMed ID: 23032419
[TBL] [Abstract][Full Text] [Related]
15. Genital Tenofovir Concentrations Correlate With Protection Against HIV Infection in the CAPRISA 004 Trial: Importance of Adherence for Microbicide Effectiveness.
Kashuba AD; Gengiah TN; Werner L; Yang KH; White NR; Karim QA; Abdool Karim SS
J Acquir Immune Defic Syndr; 2015 Jul; 69(3):264-9. PubMed ID: 26181703
[TBL] [Abstract][Full Text] [Related]
16. Tenofovir, emtricitabine intracellular and plasma, and efavirenz plasma concentration decay following drug intake cessation: implications for HIV treatment and prevention.
Jackson A; Moyle G; Watson V; Tjia J; Ammara A; Back D; Mohabeer M; Gazzard B; Boffito M
J Acquir Immune Defic Syndr; 2013 Mar; 62(3):275-81. PubMed ID: 23274933
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetic and safety analyses of tenofovir and tenofovir-emtricitabine vaginal tablets in pigtailed macaques.
Pereira LE; Clark MR; Friend DR; Garber DA; McNicholl JM; Hendry RM; Doncel GF; Smith JM
Antimicrob Agents Chemother; 2014 May; 58(5):2665-74. PubMed ID: 24566178
[TBL] [Abstract][Full Text] [Related]
18. Tenofovir, emtricitabine, and tenofovir diphosphate in dried blood spots for determining recent and cumulative drug exposure.
Castillo-Mancilla JR; Zheng JH; Rower JE; Meditz A; Gardner EM; Predhomme J; Fernandez C; Langness J; Kiser JJ; Bushman LR; Anderson PL
AIDS Res Hum Retroviruses; 2013 Feb; 29(2):384-90. PubMed ID: 22935078
[TBL] [Abstract][Full Text] [Related]
19. Pregnancy-related effects on tenofovir pharmacokinetics: a population study with 186 women.
Benaboud S; Hirt D; Launay O; Pannier E; Firtion G; Rey E; Bouazza N; Foissac F; Chappuy H; Urien S; Tréluyer JM
Antimicrob Agents Chemother; 2012 Feb; 56(2):857-62. PubMed ID: 22123690
[TBL] [Abstract][Full Text] [Related]
20. Safety, adherence and acceptability of intermittent tenofovir/emtricitabine as HIV pre-exposure prophylaxis (PrEP) among HIV-uninfected Ugandan volunteers living in HIV-serodiscordant relationships: a randomized, clinical trial.
Kibengo FM; Ruzagira E; Katende D; Bwanika AN; Bahemuka U; Haberer JE; Bangsberg DR; Barin B; Rooney JF; Mark D; Chetty P; Fast P; Kamali A; Priddy FH
PLoS One; 2013; 8(9):e74314. PubMed ID: 24086333
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
